BCAB - NASDAQ
BioAtla, Inc.
$0.89
+8.2%BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
At a Glance
Live SnapshotBioAtla, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
BioAtla, Inc. Cash Flow Statement
BCAB • NASDAQ
| BioAtla, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-69.8M | -123.5M | -106.5M | -95.4M | -35.9M | -29.9M | -29M | |
925K | 1.2M | 1.2M | 1.3M | 1M | 860K | 794K | |
0.0 | 0.0 | 0.0 | -686K | 4.5M | 6.4K | 0.0 | |
8.9M | 13.5M | 14.6M | 25.1M | 3M | -6.4K | 2.6K | |
-807K | 2K | 13K | 3K | -6.5M | -5.8M | 2.6M | |
(0.0) | (6K) | (67K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-11.2M | 4.7M | 287K | 7.4M | -2.5M | 25.1M | -9.7M | |
-71.9M | -104M | -90.4M | -62.2M | -36.3M | -9.6M | -35.3M | |
INVESTING ACTIVITIES | |||||||
(0.0) | -98K | -268K | -924K | -590K | -1.5M | -988K | |
(0.0) | (0.0) | (0.0) | (0.0) | -19K | -5K | (19K) | |
0.0 | 0.0 | 3K | 0.0 | 19K | 5K | 0.0 | |
(0.0) | -98K | -265K | -924K | -590K | -1.5M | -988K | |
FINANCING ACTIVITIES | |||||||
9.2M | 336K | 61.7M | 71M | 200.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 3.4M | 4M | 5M | |
296K | -259K | -469K | -1.9M | -19K | -5K | 19K | |
9.5M | 77K | 61.2M | 69.5M | 271.8M | 4M | 5M | |
CASH FLOW SUMMARY | |||||||
-62.4M | -104M | -29.5M | 6.4M | 234.9M | -7.2M | -31.3M | |
111.5M | 215.5M | 245M | 238.6M | 3.7M | 10.9M | 42.1M | |
49M | 111.5M | 215.5M | 245M | 238.6M | 3.7M | 10.9M | |
-71.9M | -104.1M | -90.7M | -63.1M | -36.9M | -11.2M | -36.3M |
SEC Filings
BCAB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | November 21, 2025 | November 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 22, 2025 | September 16, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 20, 2025 | June 17, 2025 | 2025 | |
8-K 8-K 2025 N/A | May 16, 2025 | May 12, 2025 | 2025 | |
S-3 S-3 N/A | May 06, 2025 | May 06, 2025 | ||
10-Q 10-Q 2025 Q1 Q1 | May 06, 2025 | March 31, 2025 | 2025 |
Related Guides
Continue your BCAB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.